Оптимизация терапии и профилактики кандидозного вульвовагинита

Г. М. Бондаренко; И. Н. Никитенко; Ю. В. Щербакова

doi:10.18370/2309-4117.2014.20.50-55

Authors

Г. М. Бондаренко Institute of Dermatology and Venereology of the NAMS of Ukraine, Kharkiv, Ukraine
И. Н. Никитенко Institute of Dermatology and Venereology of the NAM S of Ukraine, Ukraine
Ю. В. Щербакова Institute of Dermatology and Venereology of the NAM S of Ukraine, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2014.20.50-55

Keywords:

vulvovaginal candidiasis, Candida albicans, Livarol

Abstract

The article describes modern views on the problem of vulvovaginal candidiasis.
Study of the ketoconazole (Livarol) effectiveness in the treatment and prevention of vulvovaginal candidiasis in women of reproductive age was performed.
Vaginal suppository Livarol (400 mg) was administered 28 women once a day for 10 days for the treatment of vaginal candidiasis (study group). Also Vaginal suppository Livarol (400 mg) was administered once a day for 10 days for 20 women without vulvovaginal candidiasis on the background of antibiotic treatment of sexual transmitted infections to prevent the development of candidiasis infection (comparison group).
The effectiveness of the drug Livarol in the form of vaginal suppositories is demonstrated in treatment and prevention of vulvovaginal candidiasis. The presence of high-performance component of the drug – ketoconazole and polyethylene oxide bases determine the most widely use of Livarol by women with vulvovaginal candidiasis.

Author Biographies

Г. М. Бондаренко, Institute of Dermatology and Venereology of the NAMS of Ukraine, Kharkiv

MD, professor, head of the Sexually Transmitted Infections Department

И. Н. Никитенко, Institute of Dermatology and Venereology of the NAM S of Ukraine

PhD, senior researcher at the Sexually Transmitted Infections Department

Ю. В. Щербакова, Institute of Dermatology and Venereology of the NAM S of Ukraine

PhD, researcher at the Sexually Transmitted Infections Department

References

Bayramova, G.R. “Candida infection. Polyene antibiotics in the treatment of vaginal candidiasis.” Gynecology, 3(6) (2001): 212-214.
Bezruchenko, I.A. “Pathogenic yeast microorganisms. Standardized methods of laboratory diagnosis of urogenital candidiasis.” Dermatology and Venereology, 2(12) (2001): 32-36.
Gorbasenko, N.V. “Modern view on the problem and the treatment of vulvovaginitis.” Medicаl Aspects of Women’s Health, 2(2006): 12-15.
Gubergrits, N.B., Lukashevich, G.M., et al. “Candidiasis of the digestive system and mucous membranes.” Ukrainian Journal of Dermatology and Venereology, 3(2005): 44-50.
European standards for diagnostics and treatment of sexually transmitted infections. Moscow: Medical literature (2003): 272 p.
European standards for diagnostics and treatment of sexually transmitted infections. Moscow: Medical literature (2006): 264 p.
Kissina, V.I., Stepanov, J.V., et al. “Clinical features of primary and recurrent urogenital candidiasis in women and the effectiveness of Forkan depending on the species composition of Candida.” Journal of Dermatology and Venereology, 2(2002): 61-63.
Kovalenko, V.N., Viktorova, A.P., eds. Compendium 2004 – Medical remedies. – K.: Morion (2004): 1664 p.
Krasnopolskiy, V.I., Serova, O.F. “Clinical efficacy of Orungal in chronic vaginal candidiasis.” Russian Bulletin of Obstetrician- Gynecologist, 1(2003): 30-32.
Leush, S.S., Roshchina, G.F., Poltavtseva, O.F., et al. “Clinical course and treatment of various forms of urogenital candidiasis.” Dermatology, Venereology, Cosmetology Ukrainian Journal, 2(2003): 72-75.
Lysenko, B.M. “Avant-efficiency of Fluconazole in the treatment of primary and recurrent vulvovaginal candidiasis.” Health of Ukraine, 4(2005): 44.
Mirzabalaeva, A.K., Dolgo-Saburova, Y.V., Kolb, Z.K., Shurpitskaya, O.A., Klimko, N.N. “Experience of using vaginal suppositories “Livarol” in patients with acute vulvovaginal candidiasis.” Gynecology, 8(2) (2006): 11-14.
Naumkina, E.V., Rudakov, N.V., Pastuchov, V.V., et al. “Urogenital candidiasis as a mixed infection.” Problems of medical mycology, 4(2) (2002): 16-17.
Rogers, K.A., Berdall, A.D. “Recurrent vulvovaginal candidiasis and its causes.” Sexually transmitted infections, 3(2000): 22-27.
Sergeev, A.Y., Ivanov, O.L., Karaulov, A.V., Malikov, V.E., Sergeev, Y.V., Zharikova, N.E. “Vaginal candidiasis: etiology, epidemiology, pathogenesis.” Immunopathology, Allergology, Infectology, 2(2001): 85-91.
Sergeev, A.Y., Sergeev, Y.V. Candidiasis. Nature of the infection, the mechanisms of aggression and defense. Laboratory Diagnosis, Clinic and Treatment. M.: Triada (2000): 471 p.
Smetnik, V.P., Tumilovich, L.G. Non-immediate gynecology. “MIA” Moscow (2005): 629 p.
Solsky, S.Y., Osipova, L.S., Solska, T.V. “Clinical experience of Mikosyst and Hroprynozyn in patients with chronic voulvovaginitis.” Art of Treatment, 5(2005): 96-99.
Tatarchuk, T.F., Solskiy, Y.P. Endocrine Gynecology (clinical essays), K (2003): 303 p.
Centers for Diseases Control and Prevention sexually transmitted diseases treatment guidelines. MMWR (2002): 51 (No, RR-6).
Haefner, H.K. “Current evaluation and management of vulvovaginitis.” Clin. Obstet. Gynecol, 42(2) (1999): 184-195.
Mazneikova, V. ”Vaginal candidiasis – treatment protocols using miconazole and fluconazole: [article in Bulgarian].” Akush. Ginekol. (Sofiia), 42(Suppl. 2) (2003): 30-34.
Sobel, J.D., Holmes, K.K. M.P.-A., Sparlimg, P.F., Lemon, S.M., Stamm, W.E., Piot, P., Wasserheit, J.N., eds. “Vulvovaginal Candidiasis.” In: Sexually transmitted diseases. 3rd ed. NY. Me Graw-Hill (1999):
-636.
Spitzbart, H., Thust, U. ”Problems of vaginal mycoses. ” Zentralbl Gynakol, 107(24) (1985): 1520-1524.